Literature DB >> 6176247

Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis.

J J Hooks, G W Jordan, T Cupps, H M Moutsopoulos, A S Fauci, A L Notkins.   

Abstract

Recently, we found interferon in the sera of patients with systemic lupus erythematosus, rheumatoid arthritis, scleroderma, and Sjögren's syndrome. In this study, we surveyed a variety of other immunologically mediated diseases. We did not find interferon in the sera of patients with Wegener's granulomatosis, sarcoidosis, infectious mononucleosis, minimal change nephritis, kidney transplants, myasthenia gravis, or uveitis, but we did find this protein in the sera of patients with active systemic and cutaneous vasculitis. Attempts to characterize the interferon in the sera of patients with systemic lupus erythematosus and vasculitis revealed that antibody to alpha (leukocyte) interferon, but not to beta (fibroblast) interferon, partially or completely neutralized the antiviral activity. The failure of antibody to alpha interferon to completely neutralize the antiviral activity in certain specimens and the lability of the antiviral activity in some specimens to pH 2.0 treatment both suggest that more than one type of interferon was present.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176247     DOI: 10.1002/art.1780250406

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  47 in total

1.  Intracellular staining of Mx proteins in cells from peripheral blood, bone marrow and skin.

Authors:  A N al-Masri; T Werfel; D Jakschies; P von Wussow
Journal:  Mol Pathol       Date:  1997-02

Review 2.  Interferon pathway activation in systemic lupus erythematosus.

Authors:  Mary K Crow
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

3.  Serum alpha interferon and lymphocyte inclusions in systemic lupus erythematosus.

Authors:  J H Klippel; S Carette; O T Preble; R M Friedman; P M Grimley
Journal:  Ann Rheum Dis       Date:  1985-02       Impact factor: 19.103

4.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

5.  Presence of interferon and anti-interferon in patients with systemic lupus erythematosus.

Authors:  P von Wussow; D Jakschies; K Hartung; H Deicher
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

6.  Genetic manipulation of the ApoF/Stat2 locus supports an important role for type I interferon signaling in atherosclerosis.

Authors:  William R Lagor; David W Fields; Robert C Bauer; Alison Crawford; Michael C Abt; David Artis; E John Wherry; Daniel J Rader
Journal:  Atherosclerosis       Date:  2014-01-10       Impact factor: 5.162

7.  Use of monoclonal antibodies as sensitive and specific probes for biologically active human gamma-interferon.

Authors:  T W Chang; S McKinney; V Liu; P C Kung; J Vilcek; J Le
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

8.  Natural killer cell activity in inflammatory joint disease.

Authors:  R D Armstrong; G S Panayi
Journal:  Clin Rheumatol       Date:  1983-09       Impact factor: 2.980

Review 9.  Genetic associations in type I interferon related pathways with autoimmunity.

Authors:  Angélica M Delgado-Vega; Marta E Alarcón-Riquelme; Sergey V Kozyrev
Journal:  Arthritis Res Ther       Date:  2010-04-14       Impact factor: 5.156

Review 10.  Cytokines in systemic lupus erythematosus.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Curr Mol Med       Date:  2009-04       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.